Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

374 17 Immunotoxins and Recombinant Immunotoxins in Cancer Therapy
tients with adult T-cell leukemia. Cancer
Res 49: 4042±6.
95 Kreitman RJ, Chaudhary VK,
Kozak RW, FitzGerald DJP, Waldmann
TA, Pastan I (1992) Recombinant
toxins containing the variable domains
of the anti-Tac monoclonal antibody
to the interleukin-2 receptor kill
malignant cells from patients with
chronic lymphocytic leukemia. Blood
80: 2344±52.
96 Kreitman RJ, Chaudhary VK, Waldmann
T,Willingham MC, Fitz-
Gerald DJ, Pastan I (1990) The recombinant
immunotoxin anti-Tac(Fv)±Pseudomonas
exotoxin 40 is cytotoxic toward
peripheral blood malignant cells from
patients with adult T-cell leukemia. Proc
Natl Acad Sci USA 87: 8291±5.
97 Engert A, Marlin G, Amlot P, Wijdenes
J, Diehl V, Thorpe P (1991) Immunotoxins
constructed with anti-
CD25 monoclonal antibodies and deglycosylated
ricin A-chain have potent antitumor
effects against human Hodgkin
cells in vitro and solid Hodgkin tumors
in mice. Int J Cancer 49: 450±6.
98 Ghetie M-A, Richardson J,Tucker T,
Jones D, Uhr JW,Vitetta ES (1991)
Antitumor activity of Fab' and IgG-anti-
CD22 immunotoxins in disseminated
human B lymphoma grown in mice
with severe combined immunodeficiency
disease: effect on tumor cells in
extranodal sites. Cancer Res 51: 5876±80.
99 Skrepnik N, Zieske AW, Robert E,
Bravo JC, Mera R, Hunt JD (1998) Aggressive
administration of recombinant
oncotoxin AR209 (anti-ErbB-2) in athymic
nude mice implanted with orthotopic
human non-small cell lung tumours.
Eur J Cancer 34: 1628±33.
100 Waurzyniak B, Schneider EA,
Tumer N, et al. (1997) In vivo toxicity,
pharmacokinetics, and antileukemic activity
of TXU (anti-CD7)±pokeweed
antiviral protein immunotoxin. Clin
Cancer Res 3: 881±90.
101 Puri RK, Hoon DS, Leland P, et al.
(1996) Preclinical development of a recombinant
toxin containing circularly
permuted interleukin 4 and truncated
Pseudomonas exotoxin for therapy of
malignant astrocytoma. Cancer Res 56:
5631±7.
102 Jain RK (1996) Delivery of molecular
medicine to solid tumors. Science 271:
1079±80.
103 Pai LH,Wittes R, Setser A,Willingham
MC, Pastan I (1996) Treatment of
advanced solid tumors with immunotoxin
LMB-1: an antibody linked to Pseudomonas
exotoxin. Nat Med 2: 350±3.
104 Pai LH, Pastan I (1998) Clinical trials
with Pseudomonas exotoxin immunotoxins.
Curr Topics Microbiol Immunol 234:
83±96.
105 Pastan IH, Pai LH, Brinkmann U,
Fitzgerald DJ (1995) Recombinant
toxins: new therapeutic agents for cancer.
Ann NY Acad Sci 758: 345±54.
106 Pastan IH, Archer GE, McLendon RE,
et al. (1995) Intrathecal administration
of single-chain immunotoxin, LMB-7
[B3(Fv)±PE38], produces cures of carcinomatous
meningitis in a rat model.
Proc Natl Acad Sci USA 92: 2765±9.
107 Reiter Y, Pai LH, Brinkmann U,
Wang QC, Pastan I (1994) Antitumor
activity and pharmacokinetics in mice
of a recombinant immunotoxin containing
a disulfide-stabilized Fv fragment.
Cancer Res 54: 2714±8.
108 Benhar I, Reiter Y, Pai LH, Pastan I
(1995) Administration of disulfide-stabilized
Fv±immunotoxins B1(dsFv)±
PE38 and B3(dsFv)±PE38 by continuous
infusion increases their efficacy in
curing large tumor xenografts in nude
mice. Int J Cancer 62: 351±5.
109 Siegall CB, Chace D, Mixan B, et al.
(1994) In vitro and in vivo characterization
of BR96 sFv±PE40. A single-chain
immunotoxin fusion protein that cures
human breast carcinoma xenografts in
athymic mice and rats. J Immunol 152:
2377±84.
110 Wels W, Harwerth IM, Mueller M,
Groner B, Hynes NE (1992) Selective
inhibition of tumor cell growth by a recombinant
single-chain antibody-toxin
specific for the erbB-2 receptor. Cancer
Res 52: 6310±7.
111 Pai-Scherf LH,Vill J, Pearson D, et al.
(1999) Hepatotoxicity in cancer patients
receiving erb-38, a recombinant immu-